Abstract
Oligodendrogliomas (OD) are rare, diffusely infiltrating tumors, arising in the white matter of cerebral hemispheres, and displaying better sensitivity to treatment and prognosis than other gliomas. Favorable prognostic factors are low-grade, combined loss of 1p/19q, younger age, good performance status, and frontal localization. Low-grade OD usually present with seizures, whereas high-grade tumors often present with focal deficits, increased intracranial pressure or cognitive deficits. Treatment may be deferred until progression in young patients with low-grade OD presenting with seizures only. Patients with enhancing lesions, mass effect, focal deficits or increased intracranial pressure should be treated without delay. Treatment consists of resection as extensive and as safe possible. Postoperative radiotherapy is indicated for large, unresectable, or incompletely resected tumors; focal deficits; anaplastic tumors; or enhancing lesions. Adjuvant PCV chemotherapy increased progression-free survival but does not improve survival as compared to PCV given at recurrence. Chemotherapy with either PCV or temozolomide constitutes a standard for recurrent/progressive disease.
| Original language | English |
|---|---|
| Pages (from-to) | 262-272 |
| Number of pages | 11 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 66 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 2008 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Oligodendroglioma. / Van den Bent, Martin J.; Reni, Michele; Gatta, Gemma; Vecht, Charles.
In: Critical Reviews in Oncology/Hematology, Vol. 66, No. 3, 06.2008, p. 262-272.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oligodendroglioma
AU - Van den Bent, Martin J.
AU - Reni, Michele
AU - Gatta, Gemma
AU - Vecht, Charles
PY - 2008/6
Y1 - 2008/6
N2 - Oligodendrogliomas (OD) are rare, diffusely infiltrating tumors, arising in the white matter of cerebral hemispheres, and displaying better sensitivity to treatment and prognosis than other gliomas. Favorable prognostic factors are low-grade, combined loss of 1p/19q, younger age, good performance status, and frontal localization. Low-grade OD usually present with seizures, whereas high-grade tumors often present with focal deficits, increased intracranial pressure or cognitive deficits. Treatment may be deferred until progression in young patients with low-grade OD presenting with seizures only. Patients with enhancing lesions, mass effect, focal deficits or increased intracranial pressure should be treated without delay. Treatment consists of resection as extensive and as safe possible. Postoperative radiotherapy is indicated for large, unresectable, or incompletely resected tumors; focal deficits; anaplastic tumors; or enhancing lesions. Adjuvant PCV chemotherapy increased progression-free survival but does not improve survival as compared to PCV given at recurrence. Chemotherapy with either PCV or temozolomide constitutes a standard for recurrent/progressive disease.
AB - Oligodendrogliomas (OD) are rare, diffusely infiltrating tumors, arising in the white matter of cerebral hemispheres, and displaying better sensitivity to treatment and prognosis than other gliomas. Favorable prognostic factors are low-grade, combined loss of 1p/19q, younger age, good performance status, and frontal localization. Low-grade OD usually present with seizures, whereas high-grade tumors often present with focal deficits, increased intracranial pressure or cognitive deficits. Treatment may be deferred until progression in young patients with low-grade OD presenting with seizures only. Patients with enhancing lesions, mass effect, focal deficits or increased intracranial pressure should be treated without delay. Treatment consists of resection as extensive and as safe possible. Postoperative radiotherapy is indicated for large, unresectable, or incompletely resected tumors; focal deficits; anaplastic tumors; or enhancing lesions. Adjuvant PCV chemotherapy increased progression-free survival but does not improve survival as compared to PCV given at recurrence. Chemotherapy with either PCV or temozolomide constitutes a standard for recurrent/progressive disease.
UR - http://www.scopus.com/inward/record.url?scp=42749090116&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42749090116&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2007.11.007
DO - 10.1016/j.critrevonc.2007.11.007
M3 - Article
C2 - 18272388
AN - SCOPUS:42749090116
VL - 66
SP - 262
EP - 272
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 3
ER -